Rigel Pharmaceuticals, Inc. · NASDAQ:RIGL
Rigel Pharmaceuticals — Cantor Global Healthcare Conference 2026
40 slides from Rigel Pharmaceuticals's conference presentation, Sep 10, 2026
Slide 1: Cantor Global Healthcare Conference
Cantor Global Healthcare Conference September 10, 2026 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA") relating to, among other things, expected commercial launches and commercial availability, commercial, financial and clinical results,
Slide 3: Rigel's Transformational Growth Strategy
Rigel’s Transformational Growth Strategy Grow Commercial In-Licensing / Business Business Development Maintain Financial Advance Development Discipline Pipeline 3
Slide 4: In-License of VEPPANU (Vepdegestrant)
In-License of VEPPANUTM (Vepdegestrant) VEPPANU is now commercially available in the U.S. 2L+, second line-plus; ER+/HER2-, estrogen receptor-positive, human epidermal growth factor receptor 2-negative; ESR1, estrogen receptor 1 gene; ESR1m, ESR1 mutated; FDA, U.S. Food and Drug Administration; PROT
Slide 5: Rigel's Transformation to Accelerated Growth
Rigel’s Transformation to Accelerated Growth Grow Commercial In-Licensing / Business Business Development Maintain Financial Advance Development Discipline Pipeline 2030s 2025 • Growth of four commercial products • Growth from potential in-licensing / 2020 • Three commercial products M&A transaction
Slide 6: Grow Commercial Business
Grow Commercial Business rigel.
Slide 7: Q2 2026 Commercial Performance
Q2 2026 Commercial Performance Net Portfolio Sales grew $8.1M (14%) vs. Q2 2025 Net Product Sales ($M) TAVALISSE GAVRETO REZLIDHIA $47.4M 18% Growth vs. 67.0 Q2 2026 Net Product Sales Q2 2025 58.9 8.9 7.0 10.7 11.8 $10.7M (10)% Growth vs. Axis Title Q2 2026 Net Product Sales Q2 2025 47.4 40.1 $8.9M
Slide 8: Expanding Commercial Access Globally
Expanding Commercial Access Globally 8
Slide 9: Expanding Commercial Availability in Global Markets
Expanding Commercial Availability in Global Markets TAVALISSE is commercially available in key European countries (TAVLESSE), Japan, South Korea, Canada and Israel Q2 2026 Collaboration Revenues • Kissei $5.8M • Grifols $5.0M • Medison $0.3M • Others $0.6M TAVALISSE Commercial Launch • Knight announ
Slide 10: In-Licensing / Business Development
In-Licensing / Business Development
Slide 11: Vepdegestrant
vepdegestrant ‘som; rigel.
Slide 12: Approved and Available in the U.S.
APPROVED AND AVAILABLE IN THE U.S. VEPPANU is indicated for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with di
Slide 13: VEPPANU Has the Potential to Transform Rigel's Commercial Portfolio
has the Potential to Transform Rigel’s Commercial Portfolio The first and only FDA-approved PROTAC, a new class of targeted agents A novel and unique mechanism of action with the potential to be an important new therapy for 2L and 3L ER+/HER2-, ESR1m metastatic breast cancer Rigel’s proven commercia
Slide 14: PROteolysis TArgeting Chimera (PROTAC)
PROteolysis TArgeting Chimera (PROTAC) The FIRST in a novel class of drugs called heterobifunctional protein degraders The novel bifunctional design of PROTAC represents a major innovation in ER degradation VEPPANU binds to an The ubiquitin-tagged Because VEPPANU bonds estrogen receptor and estrogen
Slide 15: Vepdegestrant Addresses Significant Unmet Medical Need
Vepdegestrant Addresses Significant Unmet Medical Need 15
Slide 16: ER+/HER2-, ESR1m mBC Patient Opportunity
ER+/HER2-, ESR1m mBC Patient Opportunity The largest segment of metastatic breast cancer As patients become more exposed to endocrine and CDK4/6 inhibitor therapy, ESR1m resistance develops ctDNA testing is increasing the proportion of patients diagnosed and treated in 2L The majority of ER+/HER2- p
Slide 17: Will Enter a Dynamic Market Where Most Patients are Treated in the Community Setting
Will Enter a Dynamic Market Where Most Patients are Treated in the Community Setting Current Therapies in 2L/3L ER+/HER2-, ESR1m mBC1 Market Opportunity • Oral SERDs have been rapidly 2L 3L adopted, and are used in the majority of patients in 2L and ~30% of patients in 3L 23% 36% 38% 2% • Chemothera
Slide 18: Potential to Become a Market-leading Treatment in 2L+ ER+/HER2-, ESR1m mBC
has the Potential to Become a Market-leading Treatment in 2L+ ER+/HER2-, ESR1m Metastatic Breast Cancer (mBC) • Improved median Progression Free Survival (mPFS), Objective Response Proven Rate (ORR) and Clinical Benefit Rate (CBR) vs. fulvestrant Efficacy • Improved mPFS 2.4-fold, or 2.9 months (5.0
Slide 19: Commercialization Plans Implemented
Commercialization Plans Implemented Immediately executed launch activities upon close of the transaction Collaboration Enabling Expedited Product Availability Strong relationships with partners and execution against detailed transition plans ensured Rigel was able to have VEPPANU in our specialty di
Slide 20: Commercial Launch Phases ON TRACK
Commercial Launch Phases ON TRACK Phase 1: Now Approved Phase 2: Now Available Phase 3: Branded Campaign Since Deal Close Available Now Post-Launch (Q4) • Websites: VEPPANU.com, • Expand Awareness and • Additional Materials to 3 rigelonecare.com, Adoption through an Facilitate Patient Starts rigelme
Slide 21: Advance Development Pipeline
Advance Development Pipeline
Slide 22: Hematology and Oncology Focus Areas
Hematology and Oncology Focus Areas1 • Evaluating in a Phase 1b study for patients with R/R lower-risk MDS R289 • Updated top-line data from dose expansion phase to be shared by end of 2026 IRAK1/4 Inhibitor • Granted Fast Track and Orphan Drug designations by the FDA2 Development Program • Other po
Slide 23: R289 IRAK1/4 Inhibitor in Lower-Risk MDS
R289 IRAK1/4 Inhibitor in Lower-Risk MDS 23
Slide 24: R289 Program Value Proposition for Lower-Risk MDS
R2891 Program Value Proposition for Lower-Risk MDS • ~12,200 lower-risk MDS patients that have been previously treated2 Unmet Medical • Therapies for previously-treated transfusion dependent lower-risk MDS patients Need are lacking • Dysregulated inflammatory signaling is associated with MDS Novel •
Slide 25: Lower-Risk MDS Treatment Landscape
Lower-Risk MDS Treatment Landscape • MDS is a clonal disorder of hematopoietic stem cells (HSCs) leading to dysplasia and ineffective hematopoiesis – Consequences: Cytopenias (anemia), infections, iron overload and organ dysfunction, progression to AML • Primary goal of therapy: Reduce/limit transfu
Slide 26: R289: Phase 1b Study in Relapsed/Refractory Lower-Risk MDS
R2891: Phase 1b Study in Relapsed/Refractory Lower-Risk MDS Open-label, multicenter study to evaluate the safety, tolerability, PK and preliminary efficacy of R289 in patients with LR-MDS (NCT05308264) Key Eligibility Criteria • R/R LR-MDS or inadequate response to prior Dose Escalation Phase Dose E
Slide 27: Phase 1b Study Dose Escalation Phase Data Summary
Phase 1b Study Dose Escalation Phase Data Summary Elderly, heavily pre-treated patient population with a high baseline transfusion burden • R289 was generally well RBC Transfusion Events by Dose Group 1 tolerated with a low 250 mg QD (n=3) 2 3 incidence of Grade 3/4 4 5 cytopenias and infections 500
Slide 28: R289 Development Next Steps
R289 Development Next Steps Lower-Risk MDS • Complete enrollment of the dose expansion phase and selection of the recommended Phase 2 dose for future clinical studies (2H 2026) – Share updated top-line data from dose expansion phase by end of 2026 – Open exploratory cohort of post-ESA, treatment naï
Slide 29: Maintain Financial Discipline
Maintain Financial Discipline
Slide 30: Q2 2026 Highlights
Q2 2026 Highlights Q2 2026 Net Product Sales: Net Product Sales ($M) $67.0M TAVALISSE GAVRETO REZLIDHIA • TAVALISSE $47.4M 65.4 67.0 • GAVRETO $10.7M 64.1 • REZLIDHIA $8.9M 58.9 8.9 8.3 9.6 54.9 7.0 10.7 46.5 11.1 10.2 8.0 Q2 2026 Contract Revenues: 43.6 11.8 Axis Title 38.9 7.4 9.6 $11.7M 33.5 6.1
Slide 31: Q2 2026 Financial Overview
Q2 2026 Financial Overview (in thousands) Three Months Ended June 30, 2026 2025 Six Months Ended June 30, 2026 2025 2026 Financial Outlook Revenues • Total revenues of ~$285M to Net Product Sales $ 67,015 $ 58,948 $ 121,938 $ 102,498 Contract revenues from collaborations and other 11,688 42,737 15,5
Slide 32: Exclusive Global License Agreement to Develop, Manufacture and Commercialize VEPPANU
Exclusive Global License Agreement to Develop, Manufacture and Commercialize VEPPANUTM (vepdegestrant) Key Transaction Terms Arvinas and Pfizer will receive: • $70M upfront fee (paid in Q2 2026) • $15M upon the successful completion of certain transition activities • Additional potential milestone p
Slide 33: 2026 Progress and Key 2H 2026 Priorities
2026 Progress and Key 2H 2026 Priorities Grow Commercial Business In-Licensing / Business Development • Immediately initiated VEPPANUTM (vepdegestrant) • In-license of VEPPANUTM (vepdegestrant), an oral launch activities upon close of transaction; PROTAC with the potential to be an important new VEP
Slide 34: TAVALISSE (fostamatinib disodium hexahydrate) Tablets
TAVALISSE® (fostamatinib disodium hexahydrate) Tablets DRUG INTERACTIONS • Concomitant use of TAVALISSE with strong CYP3A4 inhibitors increases exposure to the INDICATION major active metabolite of TAVALISSE (R406), which may increase the risk of adverse • TAVALISSE® (fostamatinib disodium hexahydra
Slide 35: About REZLIDHIA (olutasidenib)
About REZLIDHIA® (olutasidenib) INDICATION REZLIDHIA is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. IMPORTANT SAFETY INFORMA
Slide 36: Important Safety Information (Cont.)
IMPORTANT SAFETY INFORMATION (Cont.) WARNINGS AND PRECAUTIONS Hepatotoxicity Monitor patients frequently for clinical symptoms of hepatic dysfunction such as fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. Obtain baseline liver function tests prior to initiation of REZL
Slide 37: About GAVRETO (pralsetinib)
About GAVRETO® (pralsetinib) INDICATIONS GAVRETO (pralsetinib) is indicated for the treatment of: • Adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test • Adult and pediatric patients 12 years of ag
Slide 38: Important Safety Information (Cont.)
IMPORTANT SAFETY INFORMATION (Cont.) • Hemorrhagic Events: Serious, including fatal, hemorrhagic events can occur with GAVRETO. Grade ≥ 3 hemorrhagic events occurred in 4.1% of patients treated with GAVRETO including one patient with a fatal hemorrhagic event. Permanently discontinue GAVRETO in pati
Slide 39: About VEPPANU (vepdegestrant)
About VEPPANUTM (vepdegestrant) INDICATION VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)–positive, The most common (≥10%) adverse reactions, including laboratory abnormalities, were human epidermal growth factor receptor 2 (HER2)–negative, estrogen receptor–1 (ESR1)– d
Slide 40: Thank You
Thank You www.rigel.com rigel.
Rigel Pharmaceuticals — Cantor Global Healthcare Conference 2026 on 6ix